Home・Listă Acțiuni・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Închisă

SectorSănătate

9.02 2.5

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

8.75

Maxim

9.02

Indicatori cheie
By Trading Economics
Venit	-1.1B -722M
Vânzări	-250M 156M
P/E Medie Sector	7.603 68.51
EPS	0.14
Marjă de profit	-461.478
Angajați	435
EBITDA	-966M -700M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+148.47% upside

Dividende
By Acuity
Următoarele câștiguri	5 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-99M 2.2B
Deschiderea anterioară	6.52
Închiderea anterioară	9.02

BioCryst Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3 aug. 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31 iul. 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30 iul. 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29 iul. 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28 iul. 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27 iul. 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24 iul. 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22 iul. 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21 iul. 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20 iul. 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Comparație

Modificare preț

BioCryst Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

148.47% sus

Prognoză pe 12 luni

Medie 21.89 USD 148.47%

Maxim 32 USD

Minim 12 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBioCryst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor BioCryst Pharmaceuticals Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.